Clinical Trial

A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases

Study acronym: JY232
Recruiting
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-28
notable Sponsor changed: Shenzhen Genocury Biotech Co., Ltd. -> Liang Zou 2026-07-28
Trial Details
NCT Number NCT07490951
Lead Sponsor Liang Zou
Conditions Autoimmune Diseases
Enrollment 20 participants
Start Date 2026-03-22
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27